We used Saccharomyces cerevisiae as a model system in which to examine the mechanism of action of the anti-Pneumocystis drug pentamidine. Pentamidine at low concentrations inhibited S. cerevisiae growth on nonfermentable carbon sources (50%o inhibitory concentration [IC50] of 1.25 ,ug/ml in glycerol). Pentamidine inhibited growth on fermentable energy sources only at much higher concentrations (IC50 of 250 ,ug/ml in glucose). Inhibition at low pentamidine concentrations in glycerol was due to cytostatic activity rather than cytotoxic or mutagenic activity. Pentamidine also rapidly inhibited respiration by intact yeast cells, although inhibitory concentrations were much higher than those inhibitory to growth (IC50 of 100 ,ug/ml for respiration).
Pentamidine also induced petite mutations, although only at concentrations much higher than those required for growth inhibition. These results suggest that a function essential for respiratory growth is inhibited by pentamidine and that pentamidine affects mitochondrial processes. We propose the hypothesis that the primary cellular target of pentamidine in S. cerevisiae is the mitochondrion.
Pentamidine is widely used for the prophylaxis and treatment of Pneumocystis carinii pneumonia in AIDS patients (32) . Pentamidine is also used to treat African trypanosomiasis and leishmaniasis (33) . Unfortunately, pentamidine is not always effective, and it frequently causes undesirable side effects (21) . Although pentamidine has been used in clinical settings for 40 years, uncertainty remains about its mechanism of action. In addition, widespread use of pentamidine as a prophylactic provokes concern over the evolution of pentamidine resistance in P. carinii (32, 35) . Resistance to pentamidine, both natural and acquired, occurs in trypanosomes (11, 17) .
Although one can investigate the effects of pentamidine on P. carinii by using immunocompromised animals (20) or an in vitro microculture test system (6) , detailed studies are hindered by the inability to culture P. carinii in vitro. Therefore, we have identified a model organism, Saccharomyces cerevisiae, that is sensitive to pentamidine under appropriate conditions and that can be readily manipulated by sophisticated biological techniques.
In phylogenetic terms, S. cerevisiae is an appropriate model for P. carinii. Considerable molecular and morphologic evidence indicates that P. carinii is a fungus (29) . Molecular similarities of P. carinii to the fungi include not only the rRNA genes (14, 30) but also many other genes, such as the dihydrofolate reductase (13) and thymidylate synthase (15) genes. An authoritative analysis of the rRNA phylogeny, including appropriate outgroups, indicates that P. carinii diverged from (or within) the Ascomycetes lineage very early in fungal evolution, such that P. carinii is as closely related to S. cerevisiae as it is to any other known fungus (5) .
Pentamidine has been implicated in the inhibition of a bewildering variety of cellular processes in various systems (10, 12, 18, 23, 25, 26) . Much recent work has focused upon the interactions of pentamidine with DNA (9, 12, 16) . Clearly, pentamidine can affect many different cellular processes. The process most critical to pentamidine inhibition in one organism may differ from that most critical to inhibition in a second organism. We have characterized the effects of pentamidine on S. cerevisiae in order to identify potential inhibitory mechanisms. The taxonomic relationship of S. cerevisiae and P. carinii suggests that these mechanisms may be similar and that they should also be examined for P. carinii.
Our results lead us to propose the hypothesis that the primary cellular target of pentamidine is the mitochondrion. We have determined that pentamidine inhibits respiration and that it induces mutations to a petite (mitochondrially deficient) phenotype. However, we conclude that these effects are probably not the primary reason why pentamidine inhibits growth under conditions that require mitochondrial function in S. cerevisiae. Fig. 1 , growth of wild-type yeast cells on glycerol medium was sensitive to low concentrations of pentamidine (IC50 of 1.25 p.g/ml). Growth in glucose medium was sensitive only at extremely high levels of pentamidine (IC50 of 250 ,ug/ml). We investigated the pentamidine sensitivity of growth on a number of other energy sources (Table 1) . Only on energy sources that required mitochondrial respiratory function was wild-type yeast growth inhibited by concentrations of pentamidine below 10 ,ug/ml.
MATERIALS AND METHODS

Reagents
Pentamidine inhibited yeast growth on all tested nitrogen sources: ammonia, urea, and glutamine (not shown). Inhibition was observed in minimal media or in complex, rich media when nonfermentable energy sources were used. (We use the term 'energy source" rather than "carbon source" because carbon is available from other components, such as amino acids, in the complex medium.) Inhibition was largely independent of the KCl (0 to 500 mM), MgCl2 (0 to 100 mM), or CaCl2 (0 to 100 mM) concentration in the medium. Addition of polyamines (0.04 mM spermine, 1 mM spermidine, or 1 mM putrescine) to the medium did not relieve inhibition.
Independence of inhibition from cell genotype. All labora- tory yeast strains that we tested were sensitive to low concentrations of pentamidine on glycerol but not on glucose. Sensitivity did vary slightly from strain to strain. Strain MGD353-46D was more sensitive than all other strains that we tested. Diploid strains were as sensitive as haploid strains. We have isolated pentamidine-resistant mutations (19) in the MGD353-46D and other cell backgrounds (22a), but we have not found such mutations in normal laboratory strain backgrounds.
Effect of the imp] mutation on pentamidine sensitivity. We observed that strain MGD353-46D was sensitive to pentamidine on galactose as well as on glycerol (Table 1) . This initially led us to believe that pentamidine sensitivity might be due to a catabolite-repressible process. However, we became aware that many laboratory strains carry a mutation, impl, in the gene encoding the galactose permease GAL2 (31). The imp] mutation renders yeast cells unable to grow on galactose in the absence of respiring mitochondria. In fact, MGD353-46D apparently carries the imp] mutation, because it was unable to grow on galactose anaerobically or in the presence of the respiratory inhibitor antimycin A (not shown). In contrast to MGD353-46D, strains wild type at the GAL2 locus grew on galactose anaerobically or in the presence of antimycin A or pentamidine. A strain disrupted at the GAL2 locus (Agal2) was more sensitive to pentamidine than an isogenic gal2(impl) mutant in galactose medium but was equally sensitive in glycerol medium (data not shown).
Effects of pentamidine on cell viability and induction of petite mutants. Pentamidine inhibition of yeast growth in glycerol medium was reversible (Fig. 2) . Yeast cells transferred from glucose medium into YPG medium with 25 ,ug of pentamidine per ml doubled once, but then the culture remained static for at least 48 h. Growth inhibition was reversed either by the addition of glucose ( Fig. 2A) , a fermentable energy source, to the inhibited culture or by the removal of pentamidine and suspension in fresh glycerol medium (Fig.  2B) . The initial doubling after suspension in glycerol medium may be due to the cell's ability to traverse the cell cycle without mitochondrial function. Growth rates in either glucose or glycerol after removal of inhibition were the same as those for cultures that had not been inhibited. This indicates that the metabolism of the viable cells was not affected by cytostasis in pentamidine. At higher levels (100 ,ug/ml), pentamidine did have a cytotoxic effect upon prolonged incubation (data not shown). Cytotoxicity may be due to a secondary toxic mechanism at high concentrations.
Agents like ethidium bromide, which binds to DNA, induce mutation and loss of the mitochondrial DNA. Yeast cells that lose or suffer mutations in mitochondrial DNA become unable to respire. Such mutants have a petite phenotype, forming smaller colonies on glucose medium and failing to grow on glycerol. Because this phenotype is similar to the results of pentamidine inhibition, we determined whether pentamidine induced petite mutations.
Exposure of yeast cells to pentamidine in glucose medium induced petite mutations ( Table 2) . Induction of petite mutations was dependent on the dose of pentamidine. However, even at the highest concentration (100 ,ug/ml), pentamidine induced petite mutations at a lower frequency than ethidium bromide at 10 ,ug/ml. Exposure to inhibitory concentrations of pentamidine in glycerol medium also induced petite mutation formation at a frequency higher than that in untreated controls (Table 2) . However, the induction of petite mutations does not account for the growth inhibition observed in glycerol, since static glycerol cultures (at 10 ,ug/ml) contained predominantly grande (respiratory-competent) yeast cells. Consistent with this conclusion, removal of pentamidine from inhibited glycerol cultures and resuspension in fresh glycerol medium released the inhibition of respiratory growth (Fig. 2B) .
Effects of pentamidine and other inhibitors on yeast growth and respiration. Pentamidine directly inhibited yeast respiration in vivo. Respiration of intact cells, measured by 02 uptake, was rapidly inhibited by pentamidine (Fig. 3A) . Known inhibitors of respiration such as antimycin A had effects on respiration similar to those of pentamidine (Fig. 3B) . As expected, inhibitors of processes other than respiration (even those that affect other mitochondrial functions) did not inhibit oxygen uptake (Fig. 3C and D) . Inhibition of oxygen uptake immediately after drug addition was dose dependent. Rapid inhibition ,ug/ml; and d, ethidium bromide, 12.5 ,ug/ml. of respiration required concentrations of pentamidine considerably higher ( Table 3 ) than those that inhibited growth on glycerol over 48 h (Fig. 1) . We have observed consistent inhibition of respiration by pentamidine, although the concentration required for inhibition varied considerably from experiment to experiment.
We determined the effects of other inhibitory compounds upon yeast growth in glucose and in glycerol (Table 3) and upon respiration (Fig. 3 and Table 3 ). Among the compounds that we tested were inhibitors of DNA topoisomerase II, mRNA translation, oxidative phosphorylation, membrane ATPases, and respiration. Nalidixic acid and hygromycin B inhibited growth on glucose as well as on glycerol, and neither inhibited respiration over a 20-min assay period. Ethidium bromide inhibited growth on glycerol at much lower concentrations than it inhibited growth on glucose but had no effect upon oxygen uptake within the 20-min assay period (Fig. 3D) . The uncoupling agent oligomycin also strongly inhibited growth on glycerol but not on glucose, and it also had no effect on respiration within the 20-min assay period (Fig. 3C) . Oligomycin did inhibit respiration after a longer exposure (not shown). N,N'-Dicyclohexylcarbodiimide (DCCD) and antimycin A inhibited growth on glycerol effectively, and at low concentrations they did not inhibit growth on glucose. However, unlike oligomycin or ethidium bromide, both compounds inhibited respiration rapidly. (Fig. 1 and Table 1 ). The IC50 for growth inhibition on glycerol was 1.25 ,ug of pentamidine isethionate per ml (equivalent to 0.7 ,ug of pentamidine per ml). Higher pentamidine concentrations were significantly more inhibitory to growth. The pentamidine IC50 for yeast growth, 2.1 ,uM, was also very similar to the IC50 observed in the Pneumocystis microculture assay, 7.3 jiM (6). These concentrations are higher than typical reported serum pentamidine concentrations (2, 7, 34) . The effective concentrations that we observed contrast with those from many other pentamidine inhibition studies in which much higher concentrations were used. For example, 50% inhibition of Escherichia coli RNA polymerase required 80 jig of pentamidine per ml (36). We do not infer from the inhibitory pentamidine concentrations that the mechanisms of inhibition are identical in S. cerevisiae and P. carinii. However, this comparison enriches the perspective on how our studies with S. cerevisiae may relate to pentamidine's effects in P. carinii.
DISCUSSION
Inhibition by low concentrations of pentamidine was reversible by removal of the drug or by change to a fermentable carbon source, indicating that the drug has a cytostatic rather than a cytotoxic effect in yeast cells (Fig. 2) . Pentamidine is also thought to have a cytostatic effect in P. carinii (as stated in reference 22).
At high concentrations, pentamidine induced a petite phenotype in a dose-dependent fashion at frequencies significantly above those of the background ( Table 2 ). The petite phenotype normally results from mutations, typically large deletions and amplifications, within the mitochondrial DNA. Such mutations occur at much higher frequency than petite phenotypes induced by nuclear mutations. Therefore, we infer that pentamidine induced the petite phenotype by inducing mutations in the yeast mitochondrial genome.
Induction of mitochondrial mutations by pentamidine is probably related to its ability to bind to DNA (9, 16) . Pentam- (12) . Topoisomerase II is also probably involved in the cleavage of trypanosome kinetoplast DNA induced by low concentrations of pentamidine (27) protozoans.
An obvious mechanism by which pentamidine could inhibit mitochondrial function would be to disrupt electron transport or oxidative phosphorylation. Respiration in cells was inhibited shortly after addition of pentamidine (Fig. 3A) . Such rapid inhibition could not be due to a mutagenic mechanism. However, the IC50 for growth (1.25 ,ug/ml) ( Fig. 1) and the IC50 for respiration (100 ,ug/ml) ( (8) . Also, pentamidine must not compete with polyamines for transport. In addition, these results contradict the hypothesis that pentamidine inhibits polyamine metabolism (10, 23) .
Proposed mechanism of inhibition of yeast growth by pentamidine. The dependence of inhibition on energy source is critical to our hypothesis that the mitochondrion is the primary cellular target of pentamidine. The inhibition of growth in fermentable energy sources at very high concentrations probably results from a secondary mechanism. However, the effects of pentamidine on respiration and on mitochondrial mutation, particularly the rapidity with which respiration was inhibited, suggest that pentamidine (or a rapidly produced metabolite [3] ) enters the mitochondrion.
Many alternative mechanisms for pentamidine action have been proposed. To assess some of these alternatives, we compared the effects of pentamidine with the effects of other drugs upon yeast growth in glucose and glycerol (Table 3) and compared their effects upon respiration (Fig. 3 and Table 3 ). All of the drugs inhibited growth on glycerol media, but only those known to affect mitochondrial processes (antimycin A, oligomycin, ethidium bromide, DCCD) inhibited growth on glycerol more effectively than they inhibited growth on glucose. As expected, neither oligomycin, an uncoupler of oxidative phosphorylation, nor ethidium bromide, a very effective mutagen of mitochondrial DNA, inhibited oxygen uptake by respiring yeast cells. Only antimycin A and DCCD, like pentamidine, inhibited growth much more effectively on glycerol than on glucose and inhibited oxygen uptake. Antimycin A is a respiratory inhibitor that blocks electron transport from the cytochrome bc, complex. DCCD is an inhibitor of the vacuolar, mitochondrial, and plasma membrane ATPases of fungi (4), but it is also a very reactive and lipid-soluble compound that inhibits electron transport complexes (1) in addition to its effects on membrane ATPases. However, although the effects of pentamidine mimic those of respiratory inhibitors, the poor correspondence of the IC50s for respiration and for growth does not support the conclusion that inhibition of respiration is the process most critical to pentamidine inhibition of mitochondrial function at low concentrations.
Pentamidine and its analogs inhibit ATP-dependent DNA topoisomerase from P. carinii and S. cerevisiae (12) . In our experiments, nalidixic acid, which inhibits type II topoisomerases, inhibited yeast growth on glycerol and glucose at similar concentrations, unlike pentamidine. We infer that if pentamidine's primary target within yeast cells is a topoisomerase, either the mitochondrial topoisomerase activity is particularly sensitive to pentamidine or pentamidine is selectively concentrated in the mitochondria. Pentamidine's intracellular distribution in yeast cells has not been determined. However, its induction of petite mutations, its ability to inhibit respiration, and its chemical properties suggest that it enters the mitochondrion. These observations suggest that inhibition of a putative mitochondrial topoisomerase could be critical to pentamidine cytostasis at low concentrations in glycerol.
Our results show that S. cerevisiae is a valuable model for studying the inhibitory effects of pentamidine. We anticipate that pentamidine may have similar effects on other fungi that rely on mitochondrial metabolism, potentially including P. carinii, which has mitochondria (37) and respires (24) . We propose that the primary cellular target of pentamidine in yeast cells is a process essential to respiratory growth, probably a mitochondrial function. Our data indicate that pentamidine can enter the mitochondrion but that inhibition of respiration is not likely to be the primary target of pentamidine inhibition.
